Tafasitamab, lenalidomide, and rituximab in relapsed or refractory follicular lymphoma (inMIND): a global, phase 3, randomised controlled trial

Journal:
The Lancet
Published:
Affiliations:
27
Authors:
22
Institutions Authors Share
Incyte Biosciences International Sàrl, Switzerland
2.038462
0.09
Hospital del Mar Medical Research Institute (IMIM), Spain
1.038462
0.05
Seoul National University Hospital (SNUH), South Korea
1.038462
0.05
Charles University (CU), Czech Republic
1.038462
0.05
Hospital Universitario 12 de Octubre, Spain
1.038462
0.05
Karolinska University Hospital, Sweden
1.038462
0.05
Laiko General Hospital of Athens, UOA, Greece
1.038462
0.05
Incyte, United States of America (USA)
1.038462
0.05
Bellvitge Biomedical Research Institute (IDIBELL), Spain
1.038462
0.05
Kindai University, Japan
1.038462
0.05
AZ Delta, Belgium
1.038462
0.05
University Hospital of Cologne, Germany
1.038462
0.05
Hôpital Saint-Louis, France
1.038462
0.05
Vivantes Klinikum am Urban, Germany
1.038462
0.05
University Hospitals Birmingham NHS Foundation Trust (UHB), United Kingdom (UK)
0.538462
0.02
Fred Hutchinson Cancer Center, United States of America (USA)
0.538462
0.02
University of Washington (UW), United States of America (USA)
0.538462
0.02
IJC-IGTP-ICO, Spain
0.538462
0.02
Autonomous University of Barcelona (UAB), Spain
0.538462
0.02
BC Cancer Agency (BCCA), PHSA, Canada
0.538462
0.02
The University of British Columbia (UBC), Canada
0.538462
0.02
University of Modena and Reggio Emilia (UNIMORE), Italy
0.538462
0.02
Flinders Medical Center (FMC), Australia
0.538462
0.02
Flinders University, Australia
0.538462
0.02
University of Birmingham, United Kingdom (UK)
0.538462
0.02
Azienda Usl di Reggio Emilia - IRCCS, Italy
0.538462
0.02